Introduction

As the 1st to market generic Clarithromycin IV in South Africa, CLARICULE provides prescribers with a safe and effective option for treating upper and lower respiratory tract infections.

We are proud to announce the launch of CLARICULE 500 mg powder for solution for infusion, medium and broad spectrum, macrolide antibiotic. CLARICULE acts by selectively binding to the ribosomes of susceptible bacteria, preventing translocation of activated amino acids and inhibiting the intracellular protein synthesis of susceptible bacteria. CLARICULE is active against several bacterial strains including: H. influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Morazella (Brahamella) catarrhalis, Neisseria gonorrhoeae, Helicobacter pylori and Campylobacter spp.

This course contains the full professional information for CLARICULE as approved by the South African Health Products Regulatory Authority.

Who Should Enrol

Pharmacists and prescribing Medical Practitioners

Course Content

Professional Information for CLARICULE included in the course:

  1. Name of Medicine
  2. Qualitative and Quantitative Composition Position
  3. Pharmaceutical Form
  4. Clinical Particulars
  5. Pharmacological Properties
  6. Pharmaceutical Particulars
  7. Holder of Certificate of registration
  8. Registration Number(s)
  9. Date of First Authorisation/Renewal of the Authorisation
  10. Date of Revision of the Text



Sponsored


Access

Important Professional Information for CLARICULE